ECT and Ketamine/Esketamine: Guiding Clinical Practice

News
Article

ECT: a gold-standard treatment for major depressive disorder. Ketamine/esketamine: a newer therapeutic option. This ACNP 2023 Annual Meeting session took a deeper look.

CONFERENCE REPORTER

Gerard Sanacora, MD, PhD, sat down with Psychiatric Times at the American College of Neuropsychopharmacology 2023 Annual Meeting to discuss the session he chaired, "Larger Scale Data Informing the Use of ECT and Ketamine/Esketamine in Severe and Treatment Resistant Major Depressive Disorder."

The reviewed studies at this session are "some of the biggest we are ever going to see," and will help guide clinical practice.

Dr Sanacora is George D. Gross and Esther S. Gross Professor of Psychiatry at the Yale University School of Medicine, the director of the Yale Depression Research Program and the co-director of the Yale-New Haven Hospital Interventional Psychiatry Service.

Related Videos
grave
heart
uncertainty
pray
leaders
medical student
bystander
fish river
Discrimination
© 2024 MJH Life Sciences

All rights reserved.